| Submission declined on 7 February 2024 by Ldm1954 (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 29 January 2024 by Ldm1954 (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. | |
Comment: Unfortunately you did not read the criteria carefully. Being cited 1500 times or so (Google scholar has 2716) is not notable, particularly with an h-factor of only 24. If you want to see what obvious notability looks like, try David Kass (physician). The gap is too large. Ldm1954 (talk) 03:18, 7 February 2024 (UTC)
- Comment: Please read carefully the notability guidelines, then rewrite. Currently this has too much bragging, as well as vast sections which have no sources. Ldm1954 (talk) 11:14, 29 January 2024 (UTC)
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Emmanuel Kamberov (born Feb 24, 1962) is a Bulgarian American scientist and inventor of technologies for Molecular Diagnostics, Genetic Screening, Reproductive Health, Infectious Diseases and Single Cell Genomics. He is the leading author of a patent invention[1][2] that led to a $75 million exit (Rubicon Genomics, Inc. acquired by Takara Holdings in 2017 [3]) The invention, known as PicoPLEX [4][5] was the first commercial technology to successfully and accurately amplify the whole genome of a single cell for molecular genetic screening of copy number variants (CNV) in in vitro fertilization (IVF)[6][7]. Together with intracytoplasmic sperm injection (ICSI), it is often referred to as assisted reproductive technology (ART). Currently, PicoPLEX (a.k.a. SurePLEX, SingleSeq) is used by over 95 percent of all in vitro fertilization (IVF) clinics globally as the core chemistry of the two main commercial platforms: the Illumina, Inc. VeriSeq [6][7] and the Thermo Fisher Scientific ReproSeq NGS [8] for genetic screening by next generation sequencing (NGS). Since its adoption in 2010, PicoPLEX (SurePLEX) has significantly improved the accuracy of preimplantation genetic screening of human embryos for IVF, lowered the percent of babies born with genetic abnormalities and appreciably reduced the incidence of multiple births in IVF [9][10]. The technology has contributed significantly to giving over eight million couples with infertility problems around the globe the chance of having healthy babies [10][11]
Early life and education edit
Emmanuel Kamberov was born in Veliko Tarnovo, Bulgaria’s ancient capital city to father Stephan Kamberov, an Orthodox priest and mother Ivanka Kamberova. He grew up in Bansko, Bulgaria. In 1991, he graduated from the Plovdiv University "Paisii Hilendarski” with a Ph.D.degree in microbiology. He taught microbiology at the Department of Biochemistry and Microbiology of the Plovdiv University "Paisii Hilendarski” since early 1988. In 1992, he permanently relocated to the U.S. along with wife, Valentina Kamberov, and older son, Steven Kamberov.
Career edit
In 1992 Dr. Kamberov enrolled in a postdoctoral research fellowship at Wayne State University’s Department of Biochemistry. In 1993 he moved to the University of Michigan where he held postdoctoral research fellow positions at the Departments of Biological Chemistry, Internal Medicine Rheumatology, and Howard Hughes Medical Institute. He joined biotechnology startup company Rubicon Genomics, Inc. in 2001 as employee number one, where he progressed from a senior scientist to a vice president of research in about seven years. After the acquisition of Rubicon Genomics, Inc. by Takara Holdings in 2017, Kamberov was appointed as a senior director of research and development at Takara Bio U.S. where he remained until 2019. During the SARS-CoV2 pandemic, Kamberov led the research and development effort to successfully develop and clinically implement a number of rapid and sensitive molecular tests for Lynx Dx and Rapid Biosense, both high complexity CLIA-certified COVID testing laboratories in the state of Michigan. In late 2022, Kamberov joined Signal Bioscience, a startup developing new molecular diagnostic detection technologies. Kamberov is a member of the New York Academy of Sciences since 1996, a certified SCENAR[12] pain therapist since 2013, and a DJ and producer of electronic music under the artist name DJ Emmo [13] [14] since 2008.
Bibliography, citations and patent inventions edit
https://scholar.google.com/citations?user=PnXSrYoAAAAJ&hl=en
https://scholar.google.com/citations?user=PnXSrYoAAAAJ&hl=en#d=gsc_md_hist&t=1707242343195
https://www.researchgate.net/profile/Emmanuel-Kamberov-3/3
https://www.sciencedirect.com/author/55398769300/emmanuel-s-kamberov
https://patents.justia.com/inventor/emmanuel-kamberov?page=2
Personal life edit
Emmanuel Kamberov lives with his wife Valentina Kamberov, a nurse at VA Hospital and younger son Benjamin Kamberov in Ann Arbor, Michigan.
References edit
- ^ US8206913B1, Kamberov, Emmanuel; Sun, Tong & Bruening, Eric et al., "Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process", issued 2012-06-26
- ^ Kamberov, Emmanuel (September 23, 2004). "Patent Images" (PDF). International Application Published Under the Patent Cooperation Treaty.
- ^ Reporter, Staff (January 18, 2017). "Takara Bio USA Holdings Completes Acquisition of Rubicon Genomics". genomeweb.
- ^ "PicoPLEX-WGA-Sales-sheet" (PDF). Rubicon Genomics.
- ^ "PicoPLEX Single Cell WGA Kit application overview". www.takarabio.com. Retrieved 2024-01-26.
- ^ a b "Scientific-publication-review-PreimplantationGeneticsTechnology" (PDF). illumina.com. October 7, 2016.
- ^ a b "SurePlex DNA Amplification System | Amplify DNA from single cells". www.illumina.com. Retrieved 2024-01-26.
- ^ "Ion ReproSeq PGS View Kit" (PDF). FisherSci.
- ^ z3525972 (2021-09-19). "IVF success rates have improved in the last decade, especially in older women: report". UNSW Newsroom. Retrieved 2024-01-27.
{{cite web}}: CS1 maint: numeric names: authors list (link) - ^ a b "S1472-6483(18)30598-4". RBMOjournal.com.
- ^ Scutti, Susan (2018-07-03). "At least 8 million IVF babies born in 40 years since historic first". CNN. Retrieved 2024-01-27.
- ^ "Technology self-healing mechanisms › Genuine SCENAR". Genuine SCENAR. Retrieved 2024-01-27.
- ^ "Dj Emmo". Spotify. Retrieved 2024-01-27.
- ^ "DJ EMMO OFFICIAL". SoundCloud. Retrieved 2024-01-27.